Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 6/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955256 | 0.82 | MYC (0.49) | TOP2AALDH1A1POLBIDO1MAOA | |
| SCHEMBL440239 | 0.79 | JAK2 (0.51) | TOP2AALDH1A1IDO1MAOAMAOB | |
| SCHEMBL2956579 | 0.77 | HTR3A (0.66) | HTR3A | |
| SCHEMBL2956585 | 0.77 | HTR3A (0.66) | HTR3A | |
| SCHEMBL7934473 | 0.77 | HTR3A (0.66) | HTR3A | |
| SCHEMBL440072 | 0.76 | DHODH (0.49) | TOP2AALDH1A1NPC1RAB9AIDO1 | |
| SCHEMBL2960028 | 0.76 | HTR3A (0.73) | HTR3A | |
| SCHEMBL28926584 | 0.75 | TOP2A (0.59) | TOP2AALDH1A1NPC1RAB9AIDO1 | |
| SCHEMBL496431 | 0.75 | MAOB (0.49) | TOP2AALDH1A1IDO1MAOAMAOB | |
| SCHEMBL206232 | 0.75 | TOP2A (0.56) | TOP2AALDH1A1POLBNPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781430-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7307094-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1853597-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR Technology, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089100-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | HTR3E, BRS3, HTR3A | FTO 4871/4885TOP2A 1421/4885ALDH1A1 3208/4885 |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | HTR3E, BRS3, HTR3A | FTO 4871/4885TOP2A 1421/4885ALDH1A1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.